Remicade is a medicine used to treat certain types of arthritis and Crohn's disease. It works by helping your body fight inflammation, which is a key part of these conditions. It's a type of treatment called an infusion, meaning it's given through a vein.
Every report comes from a Lived member, sent anonymously.
Have you tried Remicade (Infliximab) for Crohn's Disease?
Infliximab is a prescription biologic medicine that calms inflammation in several long-term autoimmune diseases, conditions in which the immune system attacks the body's own tissues. Remicade is the original brand. Inflectra (infliximab-dyyb), Renflexis (infliximab-abda) and Avsola (infliximab-axxq) are biosimilars: the US Food and Drug Administration (FDA) approved them as highly similar to Remicade, and they work the same way. An unbranded version of Remicade is also sold. All of these are given into a vein. In adults, infliximab is approved for moderately to severely active Crohn's disease and ulcerative colitis, including Crohn's disease that has formed fistulas (abnormal tunnels from the bowel to the skin, or between the rectum and vagina). It is also approved for rheumatoid arthritis, taken together with methotrexate, and for ankylosing spondylitis, psoriatic arthritis and severe plaque psoriasis when other whole-body treatments are less suitable. Children 6 and older can receive it for Crohn's disease or ulcerative colitis. For bowel disease, the approval covers people whose disease has not responded well enough to conventional treatment. Zymfentra is a separate infliximab product injected under the skin. It is approved only for adults with ulcerative colitis or Crohn's disease, as maintenance treatment after infliximab has been started by infusion.
Tumor necrosis factor alpha (TNF-alpha) is a signaling protein the immune system uses to switch on and sustain inflammation. It recruits white blood cells, prompts other inflammatory signals and stimulates enzymes that break down tissue. In these diseases, that process keeps damaging the joints, the gut lining or the skin. Infliximab is a monoclonal antibody, a lab-made protein designed to latch onto one specific target. It binds TNF-alpha and keeps it from attaching to cells, which quiets the chain of inflammation that follows. In rheumatoid and psoriatic arthritis this can slow joint damage as well as ease pain and swelling; in ulcerative colitis it can help the inflamed bowel lining heal. Researchers do not know exactly which of TNF-alpha's effects explains the benefit. TNF-alpha also helps the body contain certain infections, particularly tuberculosis and some fungal infections. Blocking it is why infection risk is the main trade-off of this treatment.
Remicade and its biosimilars are given as an intravenous (IV) infusion at an infusion center or clinic, and each infusion takes at least two hours. Treatment begins with three starting doses at weeks 0, 2 and 6, followed by maintenance infusions usually every 8 weeks (every 6 weeks for ankylosing spondylitis). The dose is calculated from body weight. If the effect wears off, the specialist may raise the dose or shorten the time between infusions, although higher or more frequent dosing also raises the risk of serious infection. A nurse watches for reactions during the infusion and for about two hours afterward, and some people are given medicine beforehand to make reactions less likely. Keeping to the schedule matters: restarting after a long break makes infusion reactions more likely. People who move to Zymfentra inject 120 mg under the skin every two weeks with a prefilled pen or syringe, after training, starting in place of their next scheduled infusion.
The most common side effects are respiratory infections such as colds, sinus infections and sore throats, along with headache, abdominal pain and infusion reactions. In clinical trials, about one in five people had a reaction during an infusion or within an hour of it, compared with one in ten given a placebo. Flushing, fever, chills, rash, itching, headache and shortness of breath are typical, and staff can slow or stop the infusion and treat them. Tell the nurse right away about hives, swelling of the face or throat, trouble breathing or swallowing, chest pain or feeling faint. A delayed reaction can appear days after an infusion, most often when treatment restarts after a break: fever, rash, joint or muscle aches, and swelling of the hands or face. Contact the care team promptly if this happens. Because infliximab weakens some immune defenses, call the care team right away about a fever, a cough that lingers, night sweats, unexplained weight loss, flu-like illness, or skin that is warm, red and painful. Less common but serious problems also need a prompt call: yellowing of the skin or eyes or dark urine (liver injury); new swelling of the ankles, sudden weight gain or worsening shortness of breath (heart failure); unusual bruising, bleeding or pale skin (low blood counts); a rash on the cheeks or arms that worsens in sunlight, with joint pain (a lupus-like reaction); and numbness, tingling, weakness or vision changes (nerve inflammation). Rarely, heart attack, stroke or a dangerous heart rhythm has occurred during an infusion or within a day of it. Sudden chest pain, weakness on one side of the body or trouble speaking in that window needs emergency care by calling 911.
Infliximab carries the FDA's most serious (boxed) warning for two risks. The first is serious infection, including tuberculosis (TB), fungal infections such as histoplasmosis, and bacterial blood infections, which can lead to hospitalization or death. The risk is higher in people over 65 and in those also taking steroids or methotrexate. Before starting, everyone is tested for latent TB, an inactive infection that can reawaken, and is treated for it first if the test is positive. TB can still develop later, so monitoring continues. Infliximab is not started during an active infection, and people who live in or travel to places where fungal infections are common, such as the Ohio and Mississippi river valleys, should tell their team. The second boxed warning concerns cancer. Lymphoma and other cancers, some fatal, have been reported in children and young people treated with TNF blockers. A rare, aggressive lymphoma called hepatosplenic T-cell lymphoma has occurred mostly in adolescent and young adult males with Crohn's disease or ulcerative colitis who were also taking azathioprine or 6-mercaptopurine, immune-suppressing pills often paired with infliximab. Adding one of those medicines makes the body less likely to form antibodies against infliximab, so whether to combine them is a genuine trade-off. Regular skin checks are recommended, and routine cervical cancer screening should continue. Hepatitis B testing comes before the first dose, because the drug can reawaken a hidden infection. Infliximab can cause new or worsening heart failure, and higher doses are not used in moderate or severe heart failure. People with multiple sclerosis or a similar nerve condition need a careful discussion first. Anyone who has had a severe allergic reaction to infliximab or to mouse proteins should not receive it. Vaccines should be brought up to date before treatment begins. Live vaccines, which contain a weakened form of the germ, are not given during treatment. Infliximab is not combined with other biologic medicines for the same conditions, such as anakinra (Kineret), abatacept (Orencia) or tocilizumab (Actemra), because infections increase without added benefit. Infliximab crosses the placenta late in pregnancy and can stay in a baby's blood for up to six months. Studies have not shown an increase in major birth defects, and active bowel disease or arthritis itself raises pregnancy risks, so the decision weighs both. A baby exposed in the womb should not receive live vaccines, such as the rotavirus vaccine, for at least six months after birth, so the baby's pediatrician needs to know.
The three starting infusions are front-loaded to build up the drug quickly, and the team judges the response over the following weeks. In Crohn's disease, someone who has not responded by about week 14 is unlikely to improve with more of the same, and a change is usually considered. Infliximab controls inflammation but does not cure the underlying disease, so it is typically continued long term for as long as it keeps working. Response can fade over time. One reason is that the body can make antibodies against infliximab, which clear it faster and make infusion reactions more likely. Taking methotrexate or a similar immune-suppressing medicine alongside it can reduce this, and the specialist may adjust the dose or interval before switching treatment. Because stopping and later restarting raises the chance of a reaction, breaks are best planned with the team. Ongoing care means regular infusion or injection visits, blood tests, attention to any infection, periodic skin checks, and planning vaccines, travel and pregnancy around treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Remicade (Infliximab), what you've noticed, or ask the community a question.